Effect of Immune Checkpoint Inhibitors Plus Chemotherapy on Advanced Gastric Cancer Patients with Elevated Serum AFP or Hepatoid Adenocarcinoma

• Main Authors: Li W, Li Q, Yu Y, Wang Y, Chen E, Chen L, Wang Z, Cui Y, Liu T
• Format: Article
• Language: English
• Published: Dove Medical Press 2020-11-01
• Series: Cancer Management and Research
• Subjects: gastric cancer; immunotherapy; alpha-fetoprotein-producing gastric cancer; hepatoid adenocarcinoma of stomach
• Online Access: https://www.dovepress.com/effect-of-immune-checkpoint-inhibitors-plus-chemotherapy-on-advanced-g-peer-reviewed-article-CMAR

Wei Li,1 Qian Li,1 Yiyi Yu,1 Yan Wang,1 Erbao Chen,1 Lingli Chen,2 Zhiming Wang,1 Yuehong Cui,1 Tianshu Liu1,3 1Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China; 2Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China; 3Center of Evidence-Based Medicine, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence: Tianshu Liu Department of OncologyZhongshan Hospital, Center of Evidence-Based Medicine, Fudan University, Shanghai, People’s Republic of ChinaEmail [e-mail]: Alpha-fetoprotein-producing gastric cancer (AFPGC) and hepatoid adenocarcinoma of stomach (HAS) are rare types of gastric cancer, with specific clinical manifestations and poor prognosis. The standardized treatment process of such cancers remains elusive. We aim to investigate the efficacy of immunotherapy combined with chemotherapy on patients with AFPGC or HAS.Patients and Methods: AFPGC and HAS patients who underwent immunotherapy and/or chemotherapy as the first-line treatment at our institute from June 2016 to December 2018 were enrolled in this observational study. Their clinicopathological characteristics, serum AFP level and treatment methods were collected. The progression-free survival (PFS) and overall survival (OS) were analyzed and compared between patients who received immunotherapy plus chemotherapy and those received chemotherapy.Results: A total of 21 patients with advanced AFPGC or HAS were included in the study and the median follow-up time was 28.0 months. Of the 21 patients, 7 patients received immunotherapy of PD-1 antibody (nivolumab) plus chemotherapy and 14 patients as control received chemotherapy with or without Herceptin/Apatinib. The median progression-free survival (mPFS) time was 5.0 months (4.3 months in the control group and 22.0 months in the immunotherapy group). The median overall survival (mOS) time of the control group was 16.0 months (14.0 months in chemotherapy alone subgroup, 20.0 months in chemotherapy plus Apatinib or Herceptin subgroup), while the mOS of patients receiving immunotherapy was not reached.Conclusion: This study suggested PD-1 checkpoint inhibitor plus chemotherapy could benefit AFPGC and HAS patients. Its mechanism of action warrants further investigation.Keywords: gastric cancer, immunotherapy, alpha-fetoprotein-producing gastric cancer, hepatoid adenocarcinoma of stomach